Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A computer-aided study of the Luwian (morpho-)syntax (SLUW)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Italy
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-06-01
End date: 2017-05-31
Duration (months): 24.0
Total project cost (EUR): 180277.2
EU funding (EUR): 180277.2
Participants: 1
Project status: CLOSED

The present project aims at analysing the morpho-syntactical features of the Luwian language working on the available texts and combining a standard linguistic analysis with the implementation of a statistical analysis of the annotated corpus. By glossing the morpho-syntactical structure of a large selection of both cuneiform and hieroglyphic inscriptions using a protocol derived from and compatible with the Penn Treebank Project and the Leiden Glossing Rules, the research will proceed by isolating, mapping and modelling the regular as well as the anomalous features of the morpho-syntax of one of the most important and still largely unexplored languages of the ancient Anatolian branch of Indo-European. The analysis will also identify and focus on the co-dependant syntactical, morphological, semantic and stylistic phenomena present in the corpus (e.g. syntactic triggering of stylistic features, dislocations, topicalisations). The results of the present research will provide the world of the Indo-European studies with the first comprehensive study ever dedicated to morpho-syntax of the Luwian language.

Keywords: luwian,anatolian,indo european,syntax
Pbx proteins as pioneer factors promoting signal specificity in mesodermal differentiation (PIOMES)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-05-01
End date: 2017-04-30
Duration (months): 24.0
Total project cost (EUR): 200194.8
EU funding (EUR): 200194.8
Participants: 1
Project status: CLOSED

The development of healthy organisms requires the formation of different cellular systems, such as a blood, bone and muscle. All these different cell types arise during embryonic life from specific pools of mesodermal progenitors (MPs). A central question is how distinct MPs are specified and ultimately why different cells respond to signalling pathways in different ways? Critical insights here are directly relevant to conceive strategies for increasing the efficiency of mesodermal differentiation aimed for treating muscular degenerative diseases. To date, in vitro, somitic mesoderm differentiation for regenerative purpose has had limited success. Wnt signalling promotes Embryonic Stem Cell (ESC) differentiation of all the MPs, including skeletal muscles. The activity of specific pioneer transcription factors (TFs) may be the key for converting Wnt signalling pathways into a specific transcriptional program. Pioneer TFs shape the chromatin landscape by opening the chromatin and allowing the recruitment of lineage specific TFs, and thus ultimately control the TF binding dynamics and the acquisition of a specific cell fate. Pbx proteins are pioneer TFs, which are specifically expressed in the primitive streak, the region of the embryo that will produce all mesoderm, and are critical for promoting mesodermal specification. Here, I will establish how Pbx proteins specify MPs and determine the competence of early mesoderm to respond to Wnt signalling. To this end, I will use mouse embryos and murine epiblast stem cells, which are analogous to human ESC (hESCs). My approach combines the strength of an in vitro ESC differentiation method, routinely used at DanStem, with chromatin immunoprecipitation and transcriptional regulation assays, which I have extensively mastered during my postdoctoral training. I expect that my findings will provide novel tools for rational design of strategies to combat genetic and degenerative muscular diseases, such as muscular dystrophies.

Keywords: pioneer transcription factors,mesodermal differentiation,mesodermal progenitors,gene regulation,muscular dystrophy
Ensuring the safest conditions in waterparks, public pools and hotel pools and facilitating crowd-based prevention across the world (SafeWaterpark)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-06-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Drowning causes the loss of 37,000 lives and 236,000 non-fatal injuries per year in swimming pools within the EU. Safety conditions for swimming pools in the EU are still generally poor and are mainly dependent on local authorities. Furthermore, there are multiple divergent regulations and a distinct lack of coordination between the different international players. However, as a result of recent legal developments in the EU, Tour Operators, hotels and travel agents are now legally obligated to prove their absolute commitment towards public safety in their swimming pool infrastructure. SafeWaterpark is a vast and outstanding set of service modules for hotels and water parks, developed in collaboration with TÜV SÜD, to perform full assessments and efficiently certify complete public pool facilities. Compiling over 600 different complex requirements, our test procedures are unique, containing a global set of standards. To improve our offer even further and raise public awareness, we are developing a crowd-based safety analysis app and portal for Tour Operators and the general public, called Pool-Reporter. Users will be able to raise alerts, send reviews and complete surveys concerning potential safety issues. Combined with an advanced system of automated sensors to collect safety data on real-time, we will be able to perform dynamic data monitoring through proprietary Machine Learning algorithms to trigger preventive and pro-active safety inspections. SafeWaterpark has already verified 10,000 installations across the EU in just over 4 years. With our unique technological developments, we will expand our services worldwide and multiply by 10 the number of inspections, allowing us to improve safety conditions for the general public and potentially reduce number of accidents by over 90% at monitored locations. This will help Tour Operators reduce legal exposure and raise our turnover to €20M by 2025. In the process, we will create over 50 direct and 200 indirect jobs.

Keywords: swimming pool safety,crowd based monitoring,testing inspection and certification
Pervasive Ubiquitous Lightwave SEnsor (PULSe)

Framework: Horizon 2020 — Industrial Leadership
Action type: Innovation actions
Countries involved: Germany,Italy,Italy,Norway,Poland,France
Call: Fast Track to Innovation Pilot (H2020-FTIPilot-2016-1, 2016)
Start date: 2017-01-01
End date: 2019-12-31
Duration (months): 36.0
Total project cost (EUR): 2572778.75
EU funding (EUR): 1987613.76
Participants: 6
Project status: CLOSED

PULSe's objective is to optimize, industrialize and create the conditions for a market exploitation of the first cost -effective Brillouin distributed sensing solution based on a synergy of innovations on interrogator equipment, strain sensing cable and open-access application support tools.

Keywords: sensing,smart monitoring,sensor networks,oilandgas,power grid,mining,botda technology
New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH) (PAH-HOPE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Ireland
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-10-01
End date: 2021-03-31
Duration (months): 30.0
Total project cost (EUR): 3570000.0
EU funding (EUR): 2499000.0
Participants: 1
Project status: CLOSED

ATXA Therapeutics Ltd is a company on a mission to offer new hope to patients with pulmonary arterial hypertension (PAH). PAH is a debilitating lung & heart disease with an urgent need for new medicines targeting different pathways than current drugs. These drugs do not effectively treat the disease, they carry serious side-effects, are poorly tolerated and only extend life-expectancy from 2.8 years (untreated) to 3.6 years (treated). ATXA has developed novel therapeutic drugs to treat PAH. ATXA’s drug target is the human Thromboxane Receptor, a pathway involved in all the clinical features of PAH. Based on evaluations in 2 independent animal models of PAH, ATXA’s lead NTP42 is predicted to be a truly disruptive disease-modifying drug, treating all aspects of PAH and greatly extending life expectancy. ATXA has completed the preclinical phase of its drug development program and has secured orphan designation from the EMA and FDA regulatory agencies for NTP42 for PAH treatment. The objective of PAH-HOPE is to advance ATXA’s drug NTP42 into clinical development, starting from scaled up drug manufacture through to securing regulatory clinical trial authorization (CTA). Securement of CTA will position ATXA to advance NTP42 to Phase I-III clinical trials through to marketing authorization and product launch in 2025. ATXA’s NTP42 fits with the current focus on value-based healthcare delivery, resulting in improved healthcare outcomes that matter to patients, physicians, payors but at lower cost of delivery. ATXA’s ambition is that NTP42 will capture 15% share of the lucrative PAH market resulting in $700m revenue within five years following global commercialization, growing to a mid-size SME with 155 employees. ATXA has 8 granted patents protecting NTP42 out to 2033 and beyond, which will address the imminent patent cliff of current PAH drugs. Moreover, ATXA’s NTP42 has platform applications in several other disease areas with blockbuster demand & market potential.

Keywords: orphan disease,pulmonary arterial hypertension,therapeutic drugs,thromboxane,drug development,life science investment
Financial Governance: Policy Implementation and Solidarity through EU funding (FINGOV)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-09-01
End date: 2021-08-31
Duration (months): 24.0
Total project cost (EUR): 187572.48
EU funding (EUR): 187572.48
Participants: 1
Project status: CLOSED

‘FINGOV – Financial Governance’ tests the hypothesis that EU funding could play a crucial role in steering policy implementation and enhancing inter-state solidarity in migration, an area European citizens identify as a key challenge for the EU. The project undertakes a cross-policy (migration and cohesion policies) and comparative (Greece and the Netherlands) analysis of the legal design and administration modes of two types of EU funding: Migration Funds and Structural and Investment Funds. It adopts an interdisciplinary approach, and combines doctrinal legal research with empirical qualitative research, incorporating findings through semi-structured interviews with institutional and civil society experts at EU level, the Netherlands and Greece. It delivers an evidence-based evaluation of EU funding’s impact to steer policy implementation and realise inter-state solidarity, yielding proposals to reform EU migration funding. Conceptually, it analyses trends the management of EU funding reveals about the changing nature of the European administrative system, advancing debates on federalism, governance and public policy. To achieve these objectives, I will be based at Maastricht University’s Centre for European Law, a top research institute, home to one of the largest groups of scholars in the world studying EU law. I will follow training in public policy and in problem based learning teaching methodologies, and will acquire transferable skills in leadership, project management, and communication under Prof. De Witte’s supervision. The research is relevant for academics, policy-makers, and civil society: I will distil findings in a journal article and a book manuscript, and formulate evidence based proposals to reform EU migration funding in a policy brief. Dissemination to the scientific and policy community will culminate in a conference. Communication targeting wider audiences will include contributions in open access blogs, online newspapers, and social media.

Keywords: administrative governance,inter state solidarity,eu funding,migration funds,cohesion funds,european union,multi level governance
Water as cosubstrate for biocatalytic redox reactions (BioAqua)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: Netherlands
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-07-01
End date: 2020-06-30
Duration (months): 60.0
Total project cost (EUR): 1998020.0
EU funding (EUR): 1998020.0
Participants: 1
Project status: CLOSED

The research proposed in BioAqua aims at breaking new ground in the area of catalysis by enabling water-driven biocatalytic redox reactions. Oxidoreductases are a class of enzymes with a very high potential for preparative organic synthesis, which is why they are increasingly used also on industrial scale. The current state-of-the-art, however, utilises valuable high-energy cosubstrates (such as glucose and alcohols) to promote oxidoreductases. Thereby valuable (and edible) building blocks are wasted as sacrificial electron donors which will have significant ethical (food for chemistry), economic and environmental consequences once redox biocatalysis is applied at scale. I envision utilizing water as sacrificial electron donor. Hence, a simple and abundant cosubstrate will be used instead of the valuable cosubstrates mentioned above. This will be a completely new approach in (bio)catalysis. However, activating water for this purpose water is extremely difficult due to its kinetic and thermodynamic inertness. To solve this problem, I propose using visible light as external energy source and advanced chemical catalysts to facilitate water oxidation. The electrons liberated in this process will be made available (for the first time) to promote oxidoreductases-catalysed transformations. BioAqua represents an entirely new paradigm in catalysis as I will bridge the gap between photocatalysis and biocatalysis enabling cleaner and more efficient reaction schemes.

Keywords: reduction reactions,oxidation reactions,biocatalysis,green chemistry
ChAnges in the Statistics of EXTremes Events in cliMatE (CaseXtreme)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Italy
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 125500.0
EU funding (EUR): 125500.0
Participants: 1
Project status: CLOSED

Most of the developing countries are widely recognised to be vulnerable to climate risks. Climate-related disasters are already undermining record growth across the world, threatening hard-won gains and vulnerable populations’ lives and livelihoods; increasing climate volatility can only exacerbate this and counteract the investments being made by countries to mitigate, prepare for and manage current weather risks. Amigo is currently working on an international funded project called eXtreme Climate Facility (XCF) and it is developing a specific multi-hazard Extreme Climate Index (ECI). This index would be based on meteorological data and designed to capture the severity and frequency of heat, drought, flood and other extreme weather events. In order to create financial vehicles that tracks the frequency and magnitude of extreme climate shocks in developing countries and provides additional financing for countries already managing their current climate risks, it becomes necessary to develop specific methodologies to identify the changes in the frequency of extreme events as also requested by international organization and countries. With such instruments, the disbursement of climate adaptation funds to countries would be entirely data-driven over a 30 year, or some long term, adaptation period; if there are no significant increases in the frequency or magnitude of extreme weather events over current climatology, then no payments would be made. Where payments are made, countries would use those funds to invest in Disaster Risk Reduction (DRR) or climate change adaption measures specified in pre-defined country-level adaptation plans. In this framework, the first level Objective of the project CaseXtreme is to identify a suitable metric for the Statistical Significance of Changes in the Statistics of Extremes (SSCSE) in order to provide the baseline for the design of innovative financial products and risk management tools.

Keywords: extreme events,climate change,climate adaptation measures
Efficient and cost-effective PLASMA surface treatment method Efficient and cost-effective PLASMA surface treatment method for flexible FILtration materials used in the separation of immiscible liquids (PLASMAFIL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Italy
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-05-01
End date: 2018-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

PLUME Srl is an innovative company founded in 2016 as a spin-off from the Plasma Prometeo Centre of the University of Milano-Bicocca. Our main business thrust is developing and marketing innovative and high-tech products based on plasma processing. Although a start-up, Plume has a combined experience of more than 20 years of applied research carried out in plasma treatment, deposition and material functionalization. Over the past year, we have focused our work on plasma processes that modify the hydrophilic and hydrophobic properties of textile, technical textile and polymeric films, gaining sound experience in surface treatment and characterisation in various fields of applications. After identifying a gap in water-oil filtration systems, we have developed PLASMAFIL, an innovative plasma surface treatment process for flexible filtration materials for the separation of immiscible liquids such as oil and water. Applied on polymeric fabric or polymeric membranes, our plasma treatment modifies the surface tension, altering both chemical properties and morphology of the filtering material surface. This improves the efficiency and durability of water filtration systems. This is done in a cost-effective manner, as PLASMAFIL does not require heat, nor solvent or coatings, therefore saving energy, materials and money. This is particularly of relevance for the oil and chemical sector where industrials are under economic, environmental and regulatory pressure to improve their oily wastewater treatment. With PLASMAFIL, we have a vision of expanding our influence and becoming renowned global suppliers of surface treatment processes and treated materials. This will see us grow sustainably, generating €9.48M cumulative revenue by 2024, with a ROI of 2.45.

Keywords: oily wastewater,plasma,wastewater treatment,membraoily wastewater,membrane technology,polyether sulfone,polypropylene,polyvinylidene,recovery,clean,water
Eco-innovative building products for sustainable construction (RE_CREATE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-06-01
End date: 2019-09-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

As the EU pushes forward to significantly reduce both its energy consumption and carbon footprint, green construction has become a top priority. Today construction and the use of building materials in the EU account for nearly 50% of Europe’s extracted materials, 50% of its energy consumption, one-third of its water consumption, and one-third of all waste generation. A dramatic change in the construction industry represents the largest potential for cost-effective emission reduction and a significant reduction in energy demand. There are also many other potential benefits from green construction, such as improved air quality, and increased thermal comfort. RE-CREATE is developing the next-generation of innovation in composite building products, made from 100% natural elements and maintaining a circular economy at all of the stages of the product life cycle. RE-CREATE is scientifically designed for mass production of building bricks, wall tiles, and 3D modular structures. CRIATERRA will introduce RE-CREATE as a very cost-effective construction material to improve energy efficiency and comfort in dwellings, while outperforming conventional materials. By our unique value proposition of materials that are structurally strong, deeply sustainable (100% natural made), exceptionally thermal resistant (6 times more than concrete) and have the bending strength of concrete, RE-CREATE will enable wide adoption of green materials. RE-CREATE is made up from 70% recycled ingredients, and the end products are 100% recyclable themselves and 100% perishable-in-nature. Our manufacturing technology drastically reduces GHG emissions (97% less than concrete), and consumes 90% less energy than ceramics. CRIATERRA aims to revolutionize construction materials just like bio-plastics are transforming the plastic industry. This is what differentiates our offer: our unique combination of sustainability, strength and affordability, enabling a circular economy in the building industry.

Keywords: green building materials,natural building products,contruction materials,energy savings,thermal resistance